Rheumatoid arthritis (RA) is a manifestation of joint inflammation. Numerous studies have confirmed that turmeric or its main active ingredient curcumin works to minimize inflammation.
A March 2012 study in India used 45 human subjects with active RA and separated separated them into three groups.
One group was given 500 mg daily of curcumin only, another group was given diclofenac sodium only, a pharmaceutical NSAID (non-steroid anti-inflammatory drug) prescribed for arthritic pain, and the third group was given a combination of turmeric and diclofenic sodium.
The curcumin-only group testing amassed the highest improvement scores, prompting the researchers to conclude: “Our study provides the first evidence for the safety and superiority of curcumin treatment in patients with active RA, and highlights the need for future large-scale trials to validate these findings in patients with RA.”
That phrase, “the need for future … trials” appears in every trial conclusion. How many trials does it take create to publicly endorse a natural remedy? And how does one have access to the thousands of early phase trials and their conclusions?
Sayer Ji, Greenmedinfo (GMI) founder pointed out in 2011 that there have been 1,800 peer reviewed studies done internationally on turmeric. Turmeric as a plant has over 1,000 phytonutrient compounds, but according to Ji, “… the medical field always attempts to isolate the magic bullet compound, in the case of turmeric, it’s curcumin.”
Read more: Natural News
